Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.

JD Gray, DA Horwitz - The Journal of clinical investigation, 1988 - Am Soc Clin Investig
JD Gray, DA Horwitz
The Journal of clinical investigation, 1988Am Soc Clin Investig
In the absence of antigenic or mitogenic stimulation, certain peripheral blood lymphocytes
exhibit proliferative and lymphokine-activated killer (LAK) cell activities when cultured with
recombinant IL-2. Both activities were found to be an exclusive property of lymphocytes
expressing type 3 complement receptors (CR3) identified by anti-CD11 monoclonal
antibodies. CD11+ lymphocytes were then fractionated into three subsets by two-color flow
cytometry. These included CD16+ cells, which display distinctive Fc receptors for IgG …
In the absence of antigenic or mitogenic stimulation, certain peripheral blood lymphocytes exhibit proliferative and lymphokine-activated killer (LAK) cell activities when cultured with recombinant IL-2. Both activities were found to be an exclusive property of lymphocytes expressing type 3 complement receptors (CR3) identified by anti-CD11 monoclonal antibodies. CD11+ lymphocytes were then fractionated into three subsets by two-color flow cytometry. These included CD16+ cells, which display distinctive Fc receptors for IgG (CD16). Using anti-CD5, the CD11+ CD16- lymphocytes were separated into non-T cell and T cell subsets. The two non-T cell subsets (CD11+ CD16+ and CD11+ CD16- CD5-), but not the T cell subset (CD11+ CD16- CD5+), could proliferate in response to IL-2. Both CD11+ non-T cell subsets, but not the CD11+ T cell subset, had the capacity to mediate natural killer cell activity. However, all three CD11+ lymphocyte subsets were capable of generating LAK activity. These findings are consistent with the concept that two signals are required to stimulate T cells to proliferate. However, at least a small subset of blood T cells can be activated by IL-2 to become LAK cells.
The Journal of Clinical Investigation